Group 1 - The core viewpoint of the news is that Haocen Medical experienced a significant stock price increase, reaching a limit up of 9.94% on August 14, with a trading price of 3.87 yuan per share and a total market capitalization of 3.251 billion yuan [1] - Haocen Medical is primarily engaged in oral medical services and industrial manufacturing, with a focus on the research and innovation of permanent magnet switch products [1] - The company was listed on the Shenzhen Stock Exchange in 2011 under the stock code 002622 and acquired a controlling stake in Guangdong Delun Medical Group Co., Ltd. in 2021 [1] Group 2 - As of March 31, Haocen Medical had 54,000 shareholders, with an average of 15,500 circulating shares per shareholder [2] - For the first quarter of 2025, Haocen Medical reported an operating income of 143 million yuan, a year-on-year decrease of 12.58%, and a net profit attributable to shareholders of -12.2146 million yuan, a year-on-year decrease of 167.13% [2]

风险提示：股市有风险，投资需谨慎。 来源：金融界 截至2025年8月13日收盘，皓宸医疗报3.52元，较前一交易日下跌1.12%。当日股价波动剧烈，最高触及 3.80元，最低下探3.35元，振幅达12.64%。全天成交194.78万手，成交金额6.90亿元。 8月13日盘中，皓宸医疗出现快速波动。早盘9点35分出现快速反弹，5分钟内涨幅超过2%；随后在10点 29分又出现快速回调，5分钟内跌幅超过2%。 资金流向方面，8月13日主力资金净流出204.57万元，占流通市值的0.07%。近五个交易日主力资金累计 净流入1.96亿元，占流通市值的6.63%。 皓宸医疗主营业务涵盖医疗服务和医疗美容领域。公司注册地位于吉林省，是一家专注于医疗健康产业 的企业。 ...

证券之星消息，8月13日医疗服务板块较上一交易日上涨4.02%，创新医疗领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流入19.62亿元，游资资金净流出7449.63万元，散户资 金净流出18.88亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | = 11.30 乙 | 11.46% | -1.00 Z | -1.02% | -10.30 Z | -10.45% | | 300759 康龙化成 | | 2.48亿 | 9.09% | 4825.42万 | 1.77% | -2.96 Z | - ...

风险提示：股市有风险，投资需谨慎。 来源:金融界 截至2025年8月12日15时，皓宸医疗股价报3.56元，较前一交易日上涨0.32元。当日开盘价为3.27元，最 高触及3.56元，最低下探3.25元，成交量为934562手，成交金额达3.24亿元。 皓宸医疗主营业务涵盖医疗服务领域，涉及医疗美容、智能电网等多个细分行业。公司总市值29.90亿 元，流通市值与总市值相同。 8月12日早盘交易时段，皓宸医疗曾出现快速回调走势，在五分钟内跌幅超过2%，当时成交额达到1.35 亿元。当日主力资金净流入11229.96万元，近五个交易日累计净流入19420.04万元。 ...

资金面上看，今日牙科医疗概念板块获主力资金净流出4.75亿元，其中，8股获主力资金净流入，净流 入资金居首的是皓宸医疗，今日主力资金净流入1.12亿元，净流入资金居前的还有美年健康、奕瑞科 技、宏盛股份等，主力资金分别净流入4540.95万元、4527.53万元、2863.59万元。 资金流入比率方面，皓宸医疗、美年健康、宏盛股份等流入比率居前，主力资金净流入率分别为 34.57%、11.58%、11.22%。（数据宝） 牙科医疗概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002622 | 皓宸医 疗 | 9.88 | 11.13 | 11196.57 | 34.57 | | 002044 | 美年健 康 | 0.19 | 1.92 | 4540.95 | 11.58 | | 688301 | 奕瑞科 技 | 4.81 | 2.37 | 4527.53 | 10.01 | | 603090 | 宏盛股 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 50.48 | -8.67% | 15.85万 | 8.11亿 | | 000504 | *ST生物 | 11.91 | -5.02% | 3.61万 | 4301.65万 | | 688710 | 益诺思 | 42.19 | -3.01% | 1.48万 | 6274.17万 | | 688222 | 成都先导 | 22.28 | -2.88% | 1 20.73万 | 4.60亿 | | 301509 | 金凯生松 | 38.46 | -2.83% | 5.59万 | 2.15亿 | | 688238 | 和元生物 | 7.61 | -2.56% | 13.40万 | 1.02亿 | | 301201 | 诚达药业 | 28.83 | -2.47% | 5.98万 | 1.73亿 | | 300149 | 香督医药 | 12.63 | -2.40% | 36.15万 | 4.58亿 | | 688621 | 阳光 ...

Group 1 - The stock of Haocen Medical reached a closing price of 3.56 yuan on August 12, with a limit-up performance and a closing order fund of 89.68 million yuan, accounting for 3.0% of its market capitalization [1] - The growth in the oral medical business is significant, with Delun Medical's sales revenue expected to increase by 13.94% year-on-year in 2024, indicating a strong expansion trend [1] - The company has improved its operational efficiency, with net profit losses narrowing by 60.06% year-on-year in 2024, signaling positive developments [1] Group 2 - Research and development expenses are projected to surge by 163% year-on-year in Q1 2025, reinforcing the company's strategic investments to enhance long-term competitiveness [1] - A new outpatient clinic in Zhaoqing is set to open in May 2025, along with the expansion of several medical facilities, increasing the number of dental chairs by over 100, thereby enhancing service capacity [1] - The company secured a 113.2 million yuan working capital loan, alleviating short-term financial pressures [1]

Group 1 - The core viewpoint of the news is that Haocen Medical experienced a significant stock price increase, reaching a limit up of 9.88% on August 12, with a trading price of 3.56 yuan per share and a total market capitalization of 2.99 billion yuan [1] - Haocen Medical is primarily engaged in oral medical services and industrial manufacturing, with a focus on the research and innovation of permanent magnet switch products [1] - The company was listed on the Shenzhen Stock Exchange in 2011 under the stock code 002622 and acquired a controlling stake in Guangdong Delun Medical Group Co., Ltd. in 2021 [1] Group 2 - As of March 31, Haocen Medical had 54,000 shareholders, with an average of 15,500 circulating shares per shareholder [2] - For the first quarter of 2025, Haocen Medical reported operating revenue of 143 million yuan, a year-on-year decrease of 12.58%, and a net profit attributable to shareholders of -12.21 million yuan, a year-on-year decrease of 167.13% [2]

Company Performance - As of August 6, 2025, Haocen Medical (002622) closed at 3.04 yuan, down 1.62% with a trading volume of 193,900 hands and a transaction amount of 59.17 million yuan [1] - The company's main business includes oral medical services and the research, production, and sales of permanent magnet switches and high/low voltage switchgear [2] Financial Metrics - Total market value of Haocen Medical is 2.55 billion yuan, significantly lower than the industry average of 19.63 billion yuan, ranking 41st out of 42 in the industry [2] - The net profit for the company is -12.21 million yuan, a decline of 167.13% year-on-year, with a net profit margin of -12.6%, ranking 36th out of 42 [2] - The company's gross profit margin stands at 38.5%, which is above the industry average of 34.85%, ranking 18th out of 42 [2] Recent Trading Activity - On August 6, 2025, the net outflow of main funds was 3.88 million yuan, accounting for 6.56% of the total transaction amount, while retail funds saw a net inflow of 5.88 million yuan, making up 9.94% of the total [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable net outflows from main funds on multiple days [1]

Group 1 - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with projected losses ranging from 28 million to 20 million yuan, compared to a profit of 0.5535 million yuan in the same period last year [1] - The expected net profit attributable to shareholders, after deducting non-recurring gains and losses, is projected to be a loss between 26 million and 19 million yuan, compared to a profit of 1.691 million yuan in the previous year [1] - Basic earnings per share are expected to be a loss between 0.0333 yuan and 0.0238 yuan, compared to earnings of 0.0007 yuan per share in the same period last year [1] Group 2 - The performance forecast has not been audited by registered accountants [1] - The decline in performance is attributed to intensified market competition in the oral medical service sector, increased customer acquisition costs, and a decrease in average transaction prices for similar products, leading to reduced profits [1] - Additionally, the company's investment income has decreased due to a decline in the valuation of financial products from its associate, Fushun Bank Co., Ltd., contributing to the overall loss for the first half of 2025 [1]